(Q41033009)

25 September 2017

1 reference

title

Influences on the quality of published drug studies (English)

1 reference

25 September 2017

2

Rennie D

1 reference

25 September 2017

Bero LA

1

1 reference

PubMed ID

8707496

25 September 2017

language of work or name

1 reference

1 January 1996

1 reference

International Journal of Technology Assessment in Health Care

25 September 2017

1 reference

25 September 2017

12

1 reference

25 September 2017

209-237

1 reference

25 September 2017

2

1 reference

Publication bias: the case for an international registry of clinical trials

25 September 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

The effects of antihypertensive therapy on the quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

How study design affects outcomes in comparisons of therapy. I: Medical

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

The medical review article: state of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Statistical power, sample size, and their reporting in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

A method for assessing the quality of a randomized control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Maintaining integrity and credibility in industry-sponsored clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Controversy in Counting and Attributing Events in Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

The continuing unethical use of placebo controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

The publication of sponsored symposiums in medical journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

3. Genetic (primary) forms of hypertriglceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Statistics in medical journals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

How much drug in the tablet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Auranofin, methotrexate, but no placebo: comment on the article by Williams et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

How much 'better' is good enough? The magnitude of treatment effect in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

GMC finds GPs guilty of fraud.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Agreement among reviewers of review articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Validation of an index of the quality of review articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Getting to grips with Archie Cochrane's agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Stanford inquiry casts doubt on 11 papers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Absolutely relative: how research results are summarized can affect treatment decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Effect of antihypertensives on sexual function and quality of life: the TAIM Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Review of company postmarketing surveillance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

The framing of decisions and the psychology of choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

More informative abstracts revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

21 January 2018

Clinical review articles

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

The FDA's critique of the anturane reinfarction trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

The case against childhood cholesterol screening

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Publication bias and the editorial process

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Cancer therapy and the randomized clinical trial. Good medicine?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Financial conflicts of interest in biomedical research

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

The quality of drug studies published in symposium proceedings

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Thrombolytic agents: the science of the art of choosing the better treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Study of information submitted by drug companies to licensing authorities

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

The publication of commercially sponsored supplements

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Sulfinpyrazone in the prevention of sudden death after myocardial infarction

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

An exploratory study of statistical assessment of papers published in the British Medical Journal

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Analysis of clinical trials by treatment actually received: is it really an option?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

The Anturane Reinfarction Trial: reevaluation of outcome

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Authorship! Authorship!

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

The importance of placebo effects in pain treatment and research

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Users' Guides to the Medical Literature

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

More on sulfinpyrazone after myocardial infarction

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

https://api.crossref.org/works/10.1017%2FS0266462300009582

1 reference

7 January 2021

Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Ethical issues relating to the conduct and interpretation of epidemiologic research in private industry

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Simplicity and complexity in conflict of interest

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Evaluating drugs after their approval for clinical use

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Why register clinical trials?--Revisited

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Underreporting research is scientific misconduct

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Editorial Peer Review in Biomedical Publication

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Minimizing the three stages of publication bias

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Regulatory process effects clinical trial registration in Spain

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

No firm basis to advocate auranofin in the treatment of juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish control authorities

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Completeness of reporting trial results: effect on physicians' willingness to prescribe

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Statistical power, sample size, and their reporting in randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Anturane reinfarction trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

The Second International Congress on Peer Review in Biomedical Publication.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Instruments for assessing the quality of drug studies published in the medical literature

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Publication bias. The triumph of hope over experience

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Evidence-based medicine. A new approach to teaching the practice of medicine

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Withholding unfavourable results in drug company sponsored clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Redundant publication

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Source of funding and outcome of clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

Breast cancer: how to mishandle misconduct.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009582

7 January 2021

10.1017/S0266462300009582

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8707496